Bristol Myers debuts first Opdualag campaign, adds to its two-combo cancer drug marketing
Bristol Myers Squibb’s first campaign for Opdualag marks a second stake in the ground for the biopharma. The new work is its second immuno-oncology combo drug, direct-to-consumer (DTC) ad campaign, with both efforts now running on TV, social and digital media.
Opdualag, approved in March 2022, is a combination of Bristol Myers’ blockbuster PD-1 Opdivo (nivolumab) and relatlimab, approved to treat advanced melanoma cancer. The second campaign is an ongoing effort for Opdivo plus Yervoy, with new creative added in December.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.